A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.

ABSTRACT:

Background

The treatment strategies for Myelodysplastic Syndromes (MDS) are usually based on the risk stratification system. However, few risk signatures which integrate the revised international prognostic scoring system (IPSS-R) with gene mutations can be easily applied in the real world.

Methods

The training cohort of 63 MDS patients was conducted at Zhongda Hospital of Southeast University from January 2013 to April 2020. The validation cohort of 141 MDS patients was obtained from GSE129828. The mutation scoring system was based on the number of mutations and a unique favorable prognostic factor, which is SF3B1 mutation. Univariate Cox, multivariate Cox, and LASSO regression analyses were used to determine the significant factors that influenced the overall survival. The

SUBMITTER: Gu S 

PROVIDER: S-EPMC7866647 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature